世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

遺伝子ベクター市場(ベクタータイプ:レンチウイルス、アデノウイルス、アデノ随伴ウイルス(AAV)、プラスミドDNA、その他、疾患:遺伝性疾患、がん、感染症、その他)-世界の産業分析、サイズ、シェア、成長、トレンド、および予測、2022-2031年


Gene Vector Market (Vector Type: Lentivirus, Adenovirus, Adeno-associated Virus (AAV), Plasmid DNA, and Others, Disease: Genetic Disorder, Cancer, Infectious Disease, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

遺伝子ベクター市場 - レポートの範囲 TMRの調査レポート「遺伝子ベクターの世界市場」は、2022年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ
2023年1月12日 US$5,795
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
190 英語

 

サマリー

遺伝子ベクター市場 - レポートの範囲
TMRの調査レポート「遺伝子ベクターの世界市場」は、2022年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会も調査しています。本レポートでは、2022年を基準年、2031年を予測年として、2017年から2031年の期間における世界の遺伝子ベクター市場の収益を提供します。また、2022年から2031年までの世界の遺伝子ベクター市場の複合年間成長率(CAGR %)を掲載しています。

本レポートは、広範な調査を経て作成されました。一次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行った。二次調査では、遺伝子ベクター市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照しました。

二次調査には、インターネットソース、政府機関、ウェブサイト、業界団体の統計データも含まれます。アナリストは、世界の遺伝子ベクター市場の様々な属性を調査するために、トップダウンアプローチとボトムアップアプローチを組み合わせて採用しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界の遺伝子ベクター市場における競争ダイナミクスの変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界の遺伝子ベクター市場への参入を検討している企業にとっても貴重なツールになります。

本レポートでは、世界の遺伝子ベクター市場の競争環境について掘り下げています。世界の遺伝子ベクター市場で活動する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の遺伝子ベクター市場のプレイヤーの属性です。

研究方法論
調査方法は、徹底的な一次調査と二次調査を組み合わせて、市場の遺伝子ベクターを分析する予定です。

二次調査

二次調査には、企業の文献、技術文書、特許データ、インターネット上の情報源、政府ウェブサイト、業界団体、機関などの統計データなどの検索が含まれます。これは、正確なデータを入手し、業界関係者の洞察を得て、ビジネスチャンスを認識するための最も信頼性が高く、効果的で成功した方法であることが証明されています。

一般的に参照する二次研究資料は、これらに限定されるものではありません:

企業ウェブサイト、プレゼンテーション、アニュアルレポート、ホワイトペーパー、テクニカルペーパー、製品パンフレット
社内外の独自データベースや関連特許の紹介
各国政府資料、統計データベース、マーケットレポートなど
市場に参入している企業に特化したニュース記事、プレスリリース、ウェブキャストを配信しています。

具体的な二次資料

- 業界の情報源
o WorldWideScience.org
o Elsevier, Inc.
o 米国国立衛生研究所(NIH)
o PubMed
o NCBI
o ヘルスケアサービス部門
- 貿易データソース
o トレードマップ
o 国連コムトレード
o トレードアトラス
- 会社情報
o OneSource Business Browser
オ・フーバーズ
o ファクティバ
O ブルームバーグ
- M&A(合併・買収
o トムソンM&Aについて
o MergerStat
o プロファウンド

一次調査

調査期間中、幅広い業界関係者やオピニオンリーダーとの綿密なインタビューやディスカッションを実施しました。調査の大部分は一次調査であり、二次調査によって補完されています。

データおよび分析の検証のため、業界関係者やコメンテーターへの一次インタビューを継続的に実施しています。典型的なリサーチ・インタビューは、以下のような機能を果たしています:

市場規模、市場動向、成長トレンド、競争環境、展望などに関する生の情報を提供します。
二次調査結果の検証や強化に役立つ
分析チームの専門知識と市場理解のさらなる発展
地域ごとの市場、カテゴリー、セグメント、サブセグメントについて、電子メールでのやりとり、電話取材、対面取材を含むプライマリーリサーチを実施。
このようなプロセスに通常参加する参加者は、これらに限定されるものではありません:

業界関係者の方マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャー、リージョナルセールスマネージャー
購買・調達担当者、技術担当者、販売代理店
外部の専門家:投資銀行、バリュエーション専門家、特定市場を専門とするリサーチアナリストなど
各業界に対応した各分野の専門家であるキーオピニオンリーダー。
主な参加者のリスト(ただし、これらに限定されない):

アドバンスト・オンコセラピーPLC
Danfysik A/S
株式会社日立製作所
IBA ワールドワイド
メビオンメディカルシステムズ株式会社

データの三角測量:二次資料・一次資料」から抽出された情報は、四半期ごとに更新される「TMR Knowledge Repository」と照合されます。

市場推定:市場規模の推定には、製品の特徴、技術の更新、地理的存在、製品の需要、販売データ(金額または数量)、過去の前年比成長率などの詳細な調査が含まれます。また、市場規模や予測を導き出すために、他のアプローチも活用した。ハードデータがない場合は、包括的なデータセットを作成するためにモデリング技法を採用した。厳密な方法論を採用し、入手可能なハードデータと以下のデータタイプを相互参照し、推定値を作成した:

人口動態データ:医療費支出、インフレ率、その他
産業指標研究開発投資、技術段階、インフラ、部門成長、設備など
市場予測:市場の促進要因、阻害要因/課題、機会を考慮し、他のセグメント/サブセグメントに対するメリット/デメリットを考慮した上で、様々なセグメントの市場予測を行います。ビジネス環境、過去の販売パターン、アンメットニーズ、競争力、国別の手術データなども、市場予測を導き出すために考慮される重要な要素のひとつです。

ページTOPに戻る


目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Vector Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Gene Vector Market Analysis and Forecasts, 2017 - 2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Technological Advancements
    5.2. Major Research Institutes Involved
    5.3. Disease Prevalence & Incidence Rate globally with key countries
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Gene Vector Market Analysis and Forecast, by Vector Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Vector Type, 2017 - 2031
        6.3.1. Lentivirus
        6.3.2. Adenovirus
        6.3.3. Adeno-associated Virus (AAV)
        6.3.4. Plasmid DNA
        6.3.5. Others
    6.4. Market Attractiveness, by Vector Type
7. Global Gene Vector Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017 - 2031
        7.3.1. Gene Therapy
        7.3.2. Vaccinology
        7.3.3. Others
    7.4. Market Attractiveness, by Application
8. Global Gene Vector Market Analysis and Forecast, by Disease
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Disease, 2017 - 2031
        8.3.1. Genetic Disorder
        8.3.2. Cancer
        8.3.3. Infectious Disease
        8.3.4. Others
    8.4. Market Attractiveness, by Disease
9. Global Gene Vector Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by End-user, 2017 - 2031
        9.3.1. Scientific Research
        9.3.2. CRO
        9.3.3. CDMO
        9.3.4. Others (Pharmaceutical, Biotechnology Companies)
    9.4. Market Attractiveness, by End-user
10. Global Gene Vector Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Country/Region
11. North America Gene Vector Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Vector Type, 2017 - 2031
        11.2.1. Lentivirus
        11.2.2. Adenovirus
        11.2.3. Adeno-associated Virus (AAV)
        11.2.4. Plasmid DNA
        11.2.5. Others
    11.3. Market Value Forecast, by Application, 2017 - 2031
        11.3.1. Gene Therapy
        11.3.2. Vaccinology
        11.3.3. Others
    11.4. Market Value Forecast, by Disease, 2017 - 2031
        11.4.1. Genetic Disorder
        11.4.2. Cancer
        11.4.3. Infectious Disease
        11.4.4. Others
    11.5. Market Value Forecast, by End-user, 2017 - 2031
        11.5.1. Scientific Research
        11.5.2. CRO
        11.5.3. CDMO
        11.5.4. Others (Pharmaceutical, Biotechnology Companies)
    11.6. Market Value Forecast, by Country, 2017 - 2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Vector Type
        11.7.2. By Application
        11.7.3. By Disease
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Gene Vector Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Vector Type, 2017 - 2031
        12.2.1. Lentivirus
        12.2.2. Adenovirus
        12.2.3. Adeno-associated Virus (AAV)
        12.2.4. Plasmid DNA
        12.2.5. Others
    12.3. Market Value Forecast, by Application, 2017 - 2031
        12.3.1. Gene Therapy
        12.3.2. Vaccinology
        12.3.3. Others
    12.4. Market Value Forecast, by Disease, 2017 - 2031
        12.4.1. Genetic Disorder
        12.4.2. Cancer
        12.4.3. Infectious Disease
        12.4.4. Others
    12.5. Market Value Forecast, by End-user, 2017 - 2031
        12.5.1. Scientific Research
        12.5.2. CRO
        12.5.3. CDMO
        12.5.4. Others (Pharmaceutical, Biotechnology Companies)
    12.6. Market Value Forecast, by Country, 2017 - 2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Spain
        12.6.5. Italy
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Vector Type
        12.7.2. By Application
        12.7.3. By Disease
        12.7.4. By End-user
        12.7.5. By Country
13. Asia Pacific Gene Vector Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Vector Type, 2017 - 2031
        13.2.1. Lentivirus
        13.2.2. Adenovirus
        13.2.3. Adeno-associated Virus (AAV)
        13.2.4. Plasmid DNA
        13.2.5. Others
    13.3. Market Value Forecast, by Application, 2017 - 2031
        13.3.1. Gene Therapy
        13.3.2. Vaccinology
        13.3.3. Others
    13.4. Market Value Forecast, by Disease, 2017 - 2031
        13.4.1. Genetic Disorder
        13.4.2. Cancer
        13.4.3. Infectious Disease
        13.4.4. Others
    13.5. Market Value Forecast, by End-user, 2017 - 2031
        13.5.1. Scientific Research
        13.5.2. CRO
        13.5.3. CDMO
        13.5.4. Others (Pharmaceutical, Biotechnology Companies)
    13.6. Market Value Forecast, by Country, 2017 - 2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Vector Type
        13.7.2. By Application
        13.7.3. By Disease
        13.7.4. By End-user
        13.7.5. By Country
14. Latin America Gene Vector Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Vector Type, 2017 - 2031
        14.2.1. Lentivirus
        14.2.2. Adenovirus
        14.2.3. Adeno-associated Virus (AAV)
        14.2.4. Plasmid DNA
        14.2.5. Others
    14.3. Market Value Forecast, by Application, 2017 - 2031
        14.3.1. Gene Therapy
        14.3.2. Vaccinology
        14.3.3. Others
    14.4. Market Value Forecast, by Disease, 2017 - 2031
        14.4.1. Genetic Disorder
        14.4.2. Cancer
        14.4.3. Infectious Disease
        14.4.4. Others
    14.5. Market Value Forecast, by End-user, 2017 - 2031
        14.5.1. Scientific Research
        14.5.2. CRO
        14.5.3. CDMO
        14.5.4. Others (Pharmaceutical, Biotechnology Companies)
    14.6. Market Value Forecast, by Country, 2017 - 2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Vector Type
        14.7.2. By Application
        14.7.3. By Disease
        14.7.4. By End-user
        14.7.5. By Country
15. Middle East & Africa Gene Vector Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Vector Type, 2017 - 2031
        15.2.1. Lentivirus
        15.2.2. Adenovirus
        15.2.3. Adeno-associated Virus (AAV)
        15.2.4. Plasmid DNA
        15.2.5. Others
    15.3. Market Value Forecast, by Application, 2017 - 2031
        15.3.1. Gene Therapy
        15.3.2. Vaccinology
        15.3.3. Others
    15.4. Market Value Forecast, by Disease, 2017 - 2031
        15.4.1. Genetic Disorder
        15.4.2. Cancer
        15.4.3. Infectious Disease
        15.4.4. Others
    15.5. Market Value Forecast, by End-user, 2017 - 2031
        15.5.1. Scientific Research
        15.5.2. CRO
        15.5.3. CDMO
        15.5.4. Others (Pharmaceutical, Biotechnology Companies)
    15.6. Market Value Forecast, by Country, 2017 - 2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Vector Type
        15.7.2. By Application
        15.7.3. By Disease
        15.7.4. By End-user
        15.7.5. By Country
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of companies)
    16.2. Market Share Analysis By Company (2021)
    16.3. Company Profiles
        16.3.1. Lonza
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Merck KGaA
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Oxford Biomedica
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. CGT Catapult
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Charles River Laboratories
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. uniQure N.V.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. FUJIFILM Diosynth Biotechnologies
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Spark Therapeutics, Inc.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Other Prominent Players

ページTOPに戻る



図表リスト

List of Tables

Table 01: Global Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 02: Global Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 04: Global Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 05: Global Gene Vector Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 07: North America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 08: North America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 09: North America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 10: North America Gene Vector Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 11: Europe Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 12: Europe Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 13: Europe Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 14: Europe Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 15: Europe Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 17: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 18: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 19: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 22: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 23: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 24: Latin America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 25: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 27: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 28: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 29: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 30: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

 

ページTOPに戻る


 

Summary

Gene Vector Market – Scope of Report
TMR’s report on the global gene vector market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global gene vector market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gene vector market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the gene vector market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global gene vector market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global gene vector market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global gene vector market.

The report delves into the competitive landscape of the global gene vector market. Key players operating in the global gene vector market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global gene vector market profiled in this report.

RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market gene vector.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.



ページTOPに戻る


Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Vector Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Gene Vector Market Analysis and Forecasts, 2017 - 2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Technological Advancements
    5.2. Major Research Institutes Involved
    5.3. Disease Prevalence & Incidence Rate globally with key countries
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Gene Vector Market Analysis and Forecast, by Vector Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Vector Type, 2017 - 2031
        6.3.1. Lentivirus
        6.3.2. Adenovirus
        6.3.3. Adeno-associated Virus (AAV)
        6.3.4. Plasmid DNA
        6.3.5. Others
    6.4. Market Attractiveness, by Vector Type
7. Global Gene Vector Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017 - 2031
        7.3.1. Gene Therapy
        7.3.2. Vaccinology
        7.3.3. Others
    7.4. Market Attractiveness, by Application
8. Global Gene Vector Market Analysis and Forecast, by Disease
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Disease, 2017 - 2031
        8.3.1. Genetic Disorder
        8.3.2. Cancer
        8.3.3. Infectious Disease
        8.3.4. Others
    8.4. Market Attractiveness, by Disease
9. Global Gene Vector Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by End-user, 2017 - 2031
        9.3.1. Scientific Research
        9.3.2. CRO
        9.3.3. CDMO
        9.3.4. Others (Pharmaceutical, Biotechnology Companies)
    9.4. Market Attractiveness, by End-user
10. Global Gene Vector Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Country/Region
11. North America Gene Vector Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Vector Type, 2017 - 2031
        11.2.1. Lentivirus
        11.2.2. Adenovirus
        11.2.3. Adeno-associated Virus (AAV)
        11.2.4. Plasmid DNA
        11.2.5. Others
    11.3. Market Value Forecast, by Application, 2017 - 2031
        11.3.1. Gene Therapy
        11.3.2. Vaccinology
        11.3.3. Others
    11.4. Market Value Forecast, by Disease, 2017 - 2031
        11.4.1. Genetic Disorder
        11.4.2. Cancer
        11.4.3. Infectious Disease
        11.4.4. Others
    11.5. Market Value Forecast, by End-user, 2017 - 2031
        11.5.1. Scientific Research
        11.5.2. CRO
        11.5.3. CDMO
        11.5.4. Others (Pharmaceutical, Biotechnology Companies)
    11.6. Market Value Forecast, by Country, 2017 - 2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Vector Type
        11.7.2. By Application
        11.7.3. By Disease
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Gene Vector Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Vector Type, 2017 - 2031
        12.2.1. Lentivirus
        12.2.2. Adenovirus
        12.2.3. Adeno-associated Virus (AAV)
        12.2.4. Plasmid DNA
        12.2.5. Others
    12.3. Market Value Forecast, by Application, 2017 - 2031
        12.3.1. Gene Therapy
        12.3.2. Vaccinology
        12.3.3. Others
    12.4. Market Value Forecast, by Disease, 2017 - 2031
        12.4.1. Genetic Disorder
        12.4.2. Cancer
        12.4.3. Infectious Disease
        12.4.4. Others
    12.5. Market Value Forecast, by End-user, 2017 - 2031
        12.5.1. Scientific Research
        12.5.2. CRO
        12.5.3. CDMO
        12.5.4. Others (Pharmaceutical, Biotechnology Companies)
    12.6. Market Value Forecast, by Country, 2017 - 2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Spain
        12.6.5. Italy
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Vector Type
        12.7.2. By Application
        12.7.3. By Disease
        12.7.4. By End-user
        12.7.5. By Country
13. Asia Pacific Gene Vector Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Vector Type, 2017 - 2031
        13.2.1. Lentivirus
        13.2.2. Adenovirus
        13.2.3. Adeno-associated Virus (AAV)
        13.2.4. Plasmid DNA
        13.2.5. Others
    13.3. Market Value Forecast, by Application, 2017 - 2031
        13.3.1. Gene Therapy
        13.3.2. Vaccinology
        13.3.3. Others
    13.4. Market Value Forecast, by Disease, 2017 - 2031
        13.4.1. Genetic Disorder
        13.4.2. Cancer
        13.4.3. Infectious Disease
        13.4.4. Others
    13.5. Market Value Forecast, by End-user, 2017 - 2031
        13.5.1. Scientific Research
        13.5.2. CRO
        13.5.3. CDMO
        13.5.4. Others (Pharmaceutical, Biotechnology Companies)
    13.6. Market Value Forecast, by Country, 2017 - 2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Vector Type
        13.7.2. By Application
        13.7.3. By Disease
        13.7.4. By End-user
        13.7.5. By Country
14. Latin America Gene Vector Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Vector Type, 2017 - 2031
        14.2.1. Lentivirus
        14.2.2. Adenovirus
        14.2.3. Adeno-associated Virus (AAV)
        14.2.4. Plasmid DNA
        14.2.5. Others
    14.3. Market Value Forecast, by Application, 2017 - 2031
        14.3.1. Gene Therapy
        14.3.2. Vaccinology
        14.3.3. Others
    14.4. Market Value Forecast, by Disease, 2017 - 2031
        14.4.1. Genetic Disorder
        14.4.2. Cancer
        14.4.3. Infectious Disease
        14.4.4. Others
    14.5. Market Value Forecast, by End-user, 2017 - 2031
        14.5.1. Scientific Research
        14.5.2. CRO
        14.5.3. CDMO
        14.5.4. Others (Pharmaceutical, Biotechnology Companies)
    14.6. Market Value Forecast, by Country, 2017 - 2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Vector Type
        14.7.2. By Application
        14.7.3. By Disease
        14.7.4. By End-user
        14.7.5. By Country
15. Middle East & Africa Gene Vector Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Vector Type, 2017 - 2031
        15.2.1. Lentivirus
        15.2.2. Adenovirus
        15.2.3. Adeno-associated Virus (AAV)
        15.2.4. Plasmid DNA
        15.2.5. Others
    15.3. Market Value Forecast, by Application, 2017 - 2031
        15.3.1. Gene Therapy
        15.3.2. Vaccinology
        15.3.3. Others
    15.4. Market Value Forecast, by Disease, 2017 - 2031
        15.4.1. Genetic Disorder
        15.4.2. Cancer
        15.4.3. Infectious Disease
        15.4.4. Others
    15.5. Market Value Forecast, by End-user, 2017 - 2031
        15.5.1. Scientific Research
        15.5.2. CRO
        15.5.3. CDMO
        15.5.4. Others (Pharmaceutical, Biotechnology Companies)
    15.6. Market Value Forecast, by Country, 2017 - 2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Vector Type
        15.7.2. By Application
        15.7.3. By Disease
        15.7.4. By End-user
        15.7.5. By Country
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of companies)
    16.2. Market Share Analysis By Company (2021)
    16.3. Company Profiles
        16.3.1. Lonza
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Merck KGaA
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Oxford Biomedica
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. CGT Catapult
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Charles River Laboratories
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. uniQure N.V.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. FUJIFILM Diosynth Biotechnologies
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Spark Therapeutics, Inc.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Other Prominent Players

ページTOPに戻る



List of Tables/Graphs

List of Tables

Table 01: Global Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 02: Global Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 04: Global Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 05: Global Gene Vector Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 07: North America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 08: North America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 09: North America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 10: North America Gene Vector Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 11: Europe Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 12: Europe Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 13: Europe Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 14: Europe Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 15: Europe Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 17: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 18: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 19: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 22: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 23: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 24: Latin America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 25: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031

Table 27: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 28: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031

Table 29: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 30: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

Transparency Market Research社の医療分野での最新刊レポート

本レポートと同じKEY WORD(cancer)の最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/13 10:29

155.97 円

166.03 円

201.39 円

ページTOPに戻る